Indeed, our data suggest that its loss may significantly mitigate disease risk by reducing the expression of several proteins (ESRP1 and DHRS2) with known deleterious effects in endometrial cancer (Supplementary Table 3) in addition to modulating cell viability and proliferative capacity. The gene discussed is ESRP1; the disease is endometrial cancer.